Key Takeaways Inogen reported a narrower Q4 adjusted loss of 15 cents as revenues rose 2% year over year.International sales jumped 14.8%, offsetting a 5.1% drop in U.S. sales and a 4.5% fall in rentals.INGN guided 2026 revenues of $366M-$373M, about 6% growth at midpoint.Inogen, Inc. (INGN) incurred an adjusted loss per share of 15 cents for fourth-quarter 2025, which was narrower than the adjusted loss per share of 24 cents in the year-ago period and the Zacks Consensus Estimate of a loss of 36 cents per ...

Inogen (INGN) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to a loss of $0.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +27.78%. A quarter ago, it was expected that this produces oxygen concentrators for patients suffering from chronic respiratory conditions would post a loss of $0.22 per share when it actually produced a loss of $0.2, delivering ...

Inogen (NasdaqGS:INGN) Q4 2025 Earnings call February 24, 2026 05:00 PM ET Company ParticipantsAnderson Schock - MedTech Equity Research AssociateJoseph Conway - Equity Research AssociateKevin Smith - President and CEOLauren Williams - Senior VP of Investor Relations and Strategic PlanningMike Bourque - CFOOperatorWelcome to Inogen's fourth quarter 2025 earnings conference call. At this time, all participants are in listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To as ...

Inogen (NasdaqGS:INGN) Q4 2025 Earnings call February 24, 2026 05:00 PM ET Company ParticipantsAnderson Schock - MedTech Equity Research AssociateJoseph Conway - Equity Research AssociateKevin Smith - President and CEOLauren Williams - Senior VP of Investor Relations and Strategic PlanningMike Bourque - CFOOperatorWelcome to Inogen's fourth quarter 2025 earnings conference call. At this time, all participants are in listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To as ...

Inogen (NasdaqGS:INGN) Q4 2025 Earnings call February 24, 2026 05:00 PM ET Speaker5Welcome to Inogen's fourth quarter 2025 earnings conference call. At this time, all participants are in listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ask a question at that time, please press star, followed by the number 1 on your touchtone phone. If anyone has difficulty hearing the conference, please press star 0 for operator assistance. As a reminder, this conference is being rec ...

February 24, 2026 Q4 2025 Supplemental Financial Information Use of Non-GAAP Financial Measures Inogen has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis for the three and twelve months ended December 31, 2025, and December 31, 2024, and for the fiscal year ended December 31, 2023. Management believes that these non-GAAP financial measures, taken in conjunction with U.S. GAAP financial measures, provide useful information for both management and investors b ...

Core Viewpoint - Inogen (INGN) shares experienced a significant increase of 6.6% to close at $6.13, driven by strong trading volume and a positive preliminary revenue update indicating steady growth and improved profitability [1][2]. Financial Performance - Inogen reported estimated fourth-quarter 2025 revenue of approximately $82 million, reflecting a year-over-year increase of about 2% [2][3]. - The full-year revenue for 2025 is projected to be around $349 million, indicating an annual growth rate of 4% [2]. - The company is expected to report a quarterly loss of $0.36 per share, which represents a year-over-year change of +12.2% [3]. Profitability and Operational Efficiency - Management indicated that Inogen is on track to achieve positive adjusted EBITDA for the full year of 2025, highlighting improvements in operating leverage, cost controls, and financial discipline [2]. Market Sentiment and Stock Performance - Despite the recent rise in stock price, the consensus EPS estimate for the upcoming quarter has been revised 5.3% lower over the last 30 days, which may indicate potential challenges ahead [5]. - The stock currently holds a Zacks Rank of 2 (Buy), suggesting a favorable outlook compared to other stocks in the same industry [6]. Industry Comparison - Inogen operates within the Zacks Medical - Instruments industry, where another company, Lucid Diagnostics Inc. (LUCD), saw a slight decline of 0.8% in its last trading session [6]. - Lucid Diagnostics has a consensus EPS estimate of -$0.07 for its upcoming report, reflecting a year-over-year change of +63.2% [7].

Core Viewpoint - Inogen (INGN) has experienced a 10% decline in stock price over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround as analysts expect better earnings than previously predicted [1]. Group 1: Technical Analysis - The Relative Strength Index (RSI) is a momentum oscillator that indicates whether a stock is oversold, with readings below 30 typically signaling this condition [2]. - INGN's current RSI reading is 29.69, indicating that heavy selling may be exhausting, which could lead to a price rebound towards previous equilibrium levels of supply and demand [5]. Group 2: Fundamental Analysis - Analysts covering INGN have raised earnings estimates for the current year, with the consensus EPS estimate increasing by 8.9% over the last 30 days, suggesting a positive outlook for price appreciation [7]. - INGN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [8].

Financial Results - Inogen, Inc. reported preliminary, unaudited revenue results for Q4 and full year 2025, with specific figures to be confirmed upon completion of audited financial statements[6] - The financial position and results of operations as of December 31, 2025, are subject to change, highlighting the need for further disclosures[6] Press Release - The press release detailing these results was issued on January 12, 2026, indicating the company's ongoing financial disclosures[6]

Core Insights - Inogen, Inc. has launched Aurora CPAP masks for Obstructive Sleep Apnea in the U.S., which is a new addition to its product portfolio [1][10] - The Aurora Mask portfolio includes various designs tailored to meet the needs of different patients, promoting patient-focused care [2] - The launch is expected to enhance Inogen's respiratory care offerings and solidify its position in the sleep apnea market [3][6] Company Performance - Following the announcement of the Aurora CPAP masks, Inogen's shares increased by nearly 7.8% [4] - The company currently has a market capitalization of $198.7 million and a price-to-sales ratio of 0.6, significantly lower than the industry average of 3.9 [5] - Inogen reported an earnings surprise of 9.1% in the last quarter [5] Market Potential - The global sleep apnea devices market is projected to grow from $4.5 billion in 2023 to $6.9 billion by 2030, with a CAGR of 6.2% [8] - Factors driving this growth include technological advancements and an increasing elderly population susceptible to sleep apnea [8] - The launch of the Aurora CPAP masks is anticipated to significantly boost Inogen's business in this expanding market [8] Strategic Goals - Inogen aims to leverage its existing distribution channels and partnerships to effectively market the Aurora CPAP masks [6][10] - The management views the launch as a crucial step towards becoming a comprehensive home care respiratory solutions provider [7]